《CELL,5月26日,A mouse model of SARS-CoV-2 infection and pathogenesis》

  • 来源专题:COVID-19科研动态监测
  • 编译者: xuwenwhlib
  • 发布时间:2020-05-27
  • A mouse model of SARS-CoV-2 infection and pathogenesis

    Shi-Hui Sun 7

    Qi Chen 7

    Hong-Jing Gu 7

    Yu-Sen Zhou

    Cheng-Feng Qin

    You-Chun Wang 8

    Show all authors

    Show footnotes

    Published:May 26, 2020DOI:https://doi.org/10.1016/j.chom.2020.05.020

    Summary

    Since December 2019, a novel coronavirus SARS-CoV-2 has emerged and rapidly spread throughout the world, resulting in a global public health emergency. The lack of vaccine and antivirals has brought an urgent need for animal model. Human Angiotensin converting enzyme II (ACE2) has been identified as a functional receptor for SARS-CoV-2. In this study, we generated a mouse model expressing human ACE2 (hACE2) using CRISPR/Cas9 knock-in technology. Compared with wild-type C57BL/6 mice, both young and aged hACE2 mice sustained high viral loads in lung, trachea and brain upon intranasal infection. Although fatalities were not observed, interstitial pneumonia and elevated cytokines were seen in SARS-CoV-2 infected- aged hACE2 mice. Interestingly, intragastric inoculation of SARS-CoV-2 was evidenced to cause productive infection and lead to pulmonary pathological changes in hACE2 mice. Overall, this animal model described here provides a useful tool for studying SARS-CoV-2 transmission and pathogenesis, and evaluating COVID-19 vaccines and therapeutics.

  • 原文来源:https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(20)30302-4
相关报告
  • 《Cell,6月10日,A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-06-11
    • A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies Ahmed O. Hassan ∗ James Brett Case ∗ Emma S. Winkler ∗ Michael J. Holtzman Ali H. Ellebedy Michael S. Diamond ¶ Published:June 10, 2020DOI:https://doi.org/10.1016/j.cell.2020.06.011 Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic with millions of human infections. One limitation to the evaluation of potential therapies and vaccines to inhibit SARS-CoV-2 infection and ameliorate disease is the lack of susceptible small animals in large numbers. Commercially available laboratory strains of mice are not readily infected by SARS-CoV-2 because of species-specific differences in their angiotensin-converting enzyme 2 (ACE2) receptors. Here, we transduced replication-defective adenoviruses encoding human ACE2 via intranasal administration into BALB/c mice and established receptor expression in lung tissues. hACE2-transduced mice were productively infected with SARS-CoV-2, and this resulted in high viral titers in the lung, lung pathology, and weight loss. Passive transfer of a neutralizing monoclonal antibody reduced viral burden in the lung and mitigated inflammation and weight loss. The development of an accessible mouse model of SARS-CoV-2 infection and pathogenesis will expedite the testing and deployment of therapeutics and vaccines.
  • 《Nature,5月26日,SARS-CoV-2 infection serology: a useful tool to overcome lockdown?》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-05-27
    • SARS-CoV-2 infection serology: a useful tool to overcome lockdown? Marzia Nuccetelli, Massimo Pieri, Sandro Grelli, Marco Ciotti, Roberto Miano, Massimo Andreoni & Sergio Bernardini Cell Death Discovery volume 6, Article number: 38 (2020) Abstract The outbreak of 2019 novel coronavirus disease (Covid-19) caused by SARS-CoV-2 has spread rapidly, inducing a progressive growth in infected patients number. Social isolation (lockdown) has been assessed to prevent and control virus diffusion, leading to a worldwide financial and political crisis. Currently, SARS-CoV-2 RNA detection in nasopharyngeal swab takes place by real-time PCR (RT-qPCR). However, molecular tests can give some false-negative results. In this context, serological assays can be useful to detect IgG/IgM antibodies, to assess the degree of immunization, to trace the contacts, and to support the decision to re-admit people at work. A lot of serological diagnostic kits have been proposed on the market but validation studies have not been published for many of them.